Most-favored-nation pricing
搜索文档
The Trump Market Medley: Tariffs, Dividends, and the Pharma Paradox
Stock Market News· 2025-12-20 18:00
Ah, the stock market. A bastion of rational thought, predictable trends, and calm, measured reactions. Or, if you’ve been paying attention to the last few years, a chaotic pinball machine where the flippers are controlled by presidential tweets and the ball bounces wildly between “historic deals” and “massive tariffs.” Welcome back to the exhilarating, if slightly whiplash-inducing, world of the Trump economy, where policy pronouncements often serve as the opening bell for a fresh round of market gymnastics ...
Trump strikes deal with US drugmakers to cut Medicaid medicine costs
The Guardian· 2025-12-19 20:14
Donald Trump and nine major pharmaceutical companies on Friday announced deals that will slash the prices of their medicines for the government’s Medicaid program and for cash payers, in his latest bid to align US costs with those in other wealthy nations.Bristol Myers Squibb, Gilead Sciences, and Merck and Roche’s US unit Genentech have struck deals. Novartis, Amgen, Boehringer Ingelheim, Sanofi and GSK have also signed on.Under the deals, each drugmaker will cut prices on most drugs sold to the Medicaid p ...
Trump secures agreements with Merck, Amgen, Novartis and others to cut drug prices under Medicaid
MINT· 2025-12-19 20:04
US President Donald Trump on Friday (December 19) announced agreements with nine major pharmaceutical companies to sharply cut the prices of medicines sold through the government’s Medicaid program and to cash-paying consumers, marking his latest push to bring US drug costs in line with those in other wealthy nations.The deals were unveiled at a White House press conference, where Trump appeared alongside senior executives from the participating drugmakers.“We were subsidizing the entire world. We’re not do ...
Pfizer to cut drug prices, announces $70 billion US investment, and discounted sales via TrumpRx
MINT· 2025-09-30 16:52
核心观点 - 辉瑞公司计划宣布降低美国处方药价格的措施 并与特朗普总统共同发布 核心内容包括对特定药品实施“最惠国”定价 推出直接面向消费者的折扣销售平台 以及宣布大规模国内投资计划 [1][2][3][4] 药品定价与销售策略 - 公司计划在美国实施广泛的药品降价 其中医疗补助计划患者将在特定药品上获得“最惠国”定价 [2] - 公司将通过一个名为“TrumpRx”的政府网站平台 推出直接面向消费者的折扣销售 允许美国人以政府谈判价格现金购买某些高销量药品 [3] - “最惠国”定价政策要求公司降低医疗补助价格 使美国未来药品价格与国外价格匹配 并建立直接面向消费者的折扣销售 [5] 公司投资与运营计划 - 公司将宣布一项700亿美元的投资计划 用于研发和国内制造 这标志着其美国业务的重大扩张 [4] 政府政策与行业背景 - 特朗普总统此前曾向包括辉瑞在内的17家主要制药商发出信函 要求其在9月29日前遵守降价要求 否则将动用一切可用工具进行应对 [6] - 除了降价 政府还向制药商施压要求增加国内生产 并计划从10月1日起 对进口品牌药或专利药征收100%的关税 除非制造商在美国建厂 [7] - 白宫发言人表示 特朗普总统正在利用联邦政府的力量大幅降低美国民众的药价 [5]